Chemotherapy for malignant pleural mesothelioma: past results and recent developments

Creative Commons License

Tomek S., Emri S., Krejcy K., Manegold C.

BRITISH JOURNAL OF CANCER, vol.88, no.2, pp.167-174, 2003 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 88 Issue: 2
  • Publication Date: 2003
  • Doi Number: 10.1038/sj.bjc.6600673
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.167-174
  • Hacettepe University Affiliated: No


This review summarises the results of previously conducted clinical trials, and subsequently presents data arising from all phase II-III studies on chemotherapy of malignant pleural mesothelioma (MPM) published since the last relevant overview, While response rates exceeding 30% have barely been achieved with established cytotoxic drugs in MPM therapy, novel chemotherapeutic agents and their combinations appear more promising. This applies especially to the anti metabolites, and in particular to pemetrexed that produced response rates of up to 45% in combination with platinum compounds. Raltitrexed combined with oxaliplatin has also been shown to be effective, and gemcitabine -applied as a single agent or in combination with cisplatin -as well as vinorelbine appear to improve the quality of life in patients presenting with MPM. Data can now be more precisely analysed by increasingly implemented randomised studies, applying a standardised staging system, and distinguishing prognostic groups. While chemotherapy for MPM remains a challenging task, important steps have clearly been made in the past years to combat this aggressive disease. The publication of pemetrexed with cisplatin phase III results in a peer-reviewed journal may soon establish a standard of care. (C) 2003 Cancer Research UK.